Klinické a mikrobiologické charakteristiky klostridiové kolitidy u dětí hospitalizovaných na KDIN v Brně v letech 2013–2017

MUSIL, Václav, Lukáš HOMOLA, M. VRBA, Adriana BRAUNOVÁ, Miriam MALÁ, Petra HOLEČKOVÁ and Lenka KRBKOVÁ. Klinické a mikrobiologické charakteristiky klostridiové kolitidy u dětí hospitalizovaných na KDIN v Brně v letech 2013–2017 (Clinical and microbiological characteristics of Clostridium difficile infection in children hospitalized at the Departement of Paediatric Infectious Diseases in Brno between 2013 and 2017). Čs. epidemiologie, mikrobiologie, imunologie. Praha: ČSL JEP, 2019, vol. 68, No 1, p. 15-22. ISSN 1210-7913.

Basic information

Original name

Klinické a mikrobiologické charakteristiky klostridiové kolitidy u dětí hospitalizovaných na KDIN v Brně v letech 2013–2017

Name (in English)

Clinical and microbiological characteristics of Clostridium difficile infection in children hospitalized at the Departement of Paediatric Infectious Diseases in Brno between 2013 and 2017

Authors

MUSIL, Václav (203 Czech Republic, guarantor, belonging to the institution), Lukáš HOMOLA (203 Czech Republic, belonging to the institution), M. VRBA (203 Czech Republic), Adriana BRAUNOVÁ (203 Czech Republic, belonging to the institution), Miriam MALÁ (203 Czech Republic, belonging to the institution), Petra HOLEČKOVÁ (203 Czech Republic, belonging to the institution) and Lenka KRBKOVÁ (203 Czech Republic, belonging to the institution)

Edition

Čs. epidemiologie, mikrobiologie, imunologie, Praha, ČSL JEP, 2019, 1210-7913

---

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

10606 Microbiology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 0.379

RIV identification code

RIV/00216224:14110/19:00110180

Organization unit

Faculty of Medicine

UT WoS

000471143400003

Keywords in English

Clostridium difficile infection; diarrhoea; fidaxomicin; children

Tags

14110318, rivok

Tags

International impact, Reviewed

---

Abstract

V originále

Cíl práce: Clostridium difficile (C. difficile) sehrává okrajovou, ale významnou úlohu v pediatrii. Cílem práce je objektivizace dat a jejich význam v klinické praxi, sdělit naše zkušenosti s léčbou pediatrických pacientů. Materiál a metodika: Sběr dat probíhal retrospektivně u pacientů (0–19 let) z pětiletého období 2013–2017 hospitalizovaných s diagnózou klostridiová kolitida na Klinice dětských infekčních nemocí (KDIN) FN Brno. Každý pacient byl testován dvoustupňovým diagnostickým algoritmem metodou imunochromatografického testu a polymerázové řetězové reakce (PCR).

In English

Aims: Clostridium difficile (C. difficile) plays a minor but important role in paediatrics. The aims of this study were to objectivise data, to show their significance in clinical practice, and to present our experience with the treatment of paediatric patients. Materials and methods: A retrospective study was conducted in patients (0-19 years of age) hospitalized for Clostridium difficile infection (CDI) in the Department of Paediatric Infectious Diseases, University Hospital in Brno between 2013 and 2017. Each patient was tested using a two-step diagnostic screening algorithm including immunochromatography and polymerase chain reaction assays. Results: Thirty-five patients with a median age of 10.3 years (range 1-17.5 years) were enrolled in the study. Almost 70% of patients were aged between 6 and 19 years. No risk factor was identified in one patient, 41.6% of cases were patients with malignancy or inflammatory bowel disease, and 2.5% of patients had short bowel syndrome. After targeted CDI treatment, the median time to resolution of diarrhoea was 2.5 days. Metronidazole was used in more than half of cases. Five patients received fidaxomicin, which was well tolerated. Metronidazole failed in three cases. Recurrence after incomplete treatment with metronidazole occurred in one patient. Health care-associated CDI was recorded in 86% of cases. Recurrent CDI was reported in four children (two with malignancy, one with inflammatory bowel dissease, and one with short bowel syndrome). Conclusions: The course of CDI is generally mild in the paediatric population. CDI without a risk factor is rare. Paediatric patients respond well to metronidazole. Fidaxomicin was well tolerated by all patients. We prefer the treatment with fidaxomicin in high-risk groups (immunocompromised condition, inflammatory bowel disease, and short bowel syndrome).